Novo Nordisk's Denecimig Achieves 99% Reduction in Bleeding Episodes for Hemophilia A Patients in Phase 3 Trial

Novo NordiskSearch company's investigational hemophilia ASearch disease treatment denecimigSearch drug has demonstrated unprecedented efficacy in reducing bleeding episodes, according to pivotal phase 3 results published in the New England Journal of Medicine. The FRONTIER2 trial showed that the bispecific antibody reduced annualized bleeding rates by up to 99% compared to on-demand treatment and by 43-54% versus prior clotting factor prophylaxis in adults and adolescents with hemophilia A.

Breakthrough Efficacy Results

The 26-week FRONTIER2 study evaluated 254 participants aged 12 years and older with hemophilia ASearch disease, both with and without Factor VIIISearch term inhibitors. Patients receiving once-monthly denecimigSearch drug experienced nearly 99% fewer bleeding episodes compared to on-demand treatment and approximately 43% fewer bleeds than their previous preventive clotting factor therapy. Those on once-weekly dosing saw approximately 96% fewer bleeds versus on-demand treatment and about 54% fewer bleeds compared to prior prophylaxis.

"The prevention and reduction of bleeding episodes is the ultimate goal for people living with hemophilia ASearch disease," said Dr. Maria Elisa Mancuso, Senior Consultant in Hematology at the Center for Thrombosis and Haemorrhagic Diseases, IRCCS Humanitas Research Hospital in Milan, Italy and lead investigator of the trial. "These results from the FRONTIER2 study provide important data on the potential of denecimigSearch drug as a preventive treatment option regardless of hemophilia A severity or inhibitor status."

Remarkable Zero-Bleed Rates

The study revealed striking differences in participants achieving zero treated bleeding episodes. Among the four denecimigSearch drug treatment arms, 64-95% of participants reported zero treated bleeds, depending on the specific arm. In contrast, comparator arms showed zero treated bleeds in only 0-37% of participants, with 0% in the on-demand arm, 33% in the pre-study clotting factor prophylaxis arm transitioning to once-weekly denecimig, and 37% in the pre-study prophylaxis arm moving to once-monthly denecimig.

Study Population and Design

Of the 254 enrolled patients, 246 completed the 26-week main phase. The study population included four females (2%), 66 adolescents aged 12-17 years (26%), 212 patients with severe hemophilia ASearch disease (84%), and 31 patients with FVIII inhibitors (12%). The trial's primary endpoint was the mean annualized bleeding rate of treated bleeds.

Safety Profile

DenecimigSearch drug demonstrated a favorable safety profile throughout the study period. No thromboembolic events or clinical evidence of neutralizing anti-denecimig antibodies were reported. Injection-site reactions occurred in 10% of participants, with reactions observed in 2.6% of total injections administered.

Mechanism of Action and Regulatory Status

DenecimigSearch drug is an investigational Factor VIIIaSearch term mimetic bispecific antibody administered subcutaneously. The drug mimics Factor VIIIa function by bridging Factor IXaSearch term and Factor XSearch term, helping restore the body's thrombin generation capacity and enabling proper blood clotting. This mechanism allows it to work effectively in patients both with and without Factor VIIISearch term inhibitors.

"With denecimigSearch drug recently submitted to the FDA through a Biologics License Application, these NEJM data further underscore its potential as a preventive treatment option that may help address the persistent unmet needs of people living with hemophilia ASearch disease, with or without inhibitors," said Anna Windle, PhD, Head of Clinical Development, Medical & Regulatory Affairs at Novo NordiskSearch company US Operations.

Novo NordiskSearch company submitted denecimigSearch drug for FDA review through a Biologics License Application in September 2025, marking a significant regulatory milestone for the investigational treatment.

Addressing Unmet Medical Need

Hemophilia ASearch disease affects approximately 836,000 people worldwide according to the World Federation of Hemophilia, representing 80-85% of all hemophilia cases. The condition is caused by missing or defective clotting Factor VIIISearch term, and approximately 30% of patients develop inhibitors that can render standard replacement therapy ineffective.

The FRONTIER2 results represent part of Novo NordiskSearch company's broader FRONTIER program, which includes studies FRONTIER1-5 investigating denecimigSearch drug across pediatric and adult populations with hemophilia ASearch disease. The comprehensive program aims to establish denecimig as a preventive treatment option with flexible dosing frequencies ranging from once-weekly to once-monthly administration.